H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on Humanigen (HGEN – Research Report) today. The company’s shares closed yesterday at $0.22.
According to TipRanks, Pantginis is an analyst with an average return of -20.0% and a 26.30% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and Celldex.
The word on The Street in general, suggests a Hold analyst consensus rating for Humanigen with a $1.50 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Humanigen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.04 million and a GAAP net loss of $30.15 million. In comparison, last year the company earned a revenue of $1.04 million and had a GAAP net loss of $70.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.
Read More on HGEN:
- Analysts’ Top Healthcare Picks: Zealand Pharma (ZEAL), POINT Biopharma Global (PNT)
- August’s Top Malware: Emotet Knocked off Top Spot by FormBook while GuLoader and Joker Disrupt the Index
- Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
- LMP Automotive Holdings, Inc. Announces its Affiliates Entered into All-Cash Sale Agreements for its Remaining Dealership and its Associated Real Estate
- Coda Octopus Group Reports Fiscal 2022 Third Quarter and Nine-Month Period Financial Results
